LPL Financial LLC Sells 6,841 Shares of TransMedics Group, Inc. $TMDX

Key Points

• LPL Financial LLC has reduced its holdings in TransMedics Group, Inc. by 25.9%, selling 6,841 shares and now owns 19,545 shares valued at approximately $1.31 million.
• During the first quarter, various hedge funds significantly increased their positions in TransMedics, with GAMMA Investing LLC boosting its holdings by 551.7%.
• Analysts have upgraded the stock's ratings, with Piper Sandler raising the target price from $125 to $145 and an overall consensus rating of "Moderate Buy" on the stock.

LPL Financial LLC decreased its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 25.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,545 shares of the company's stock after selling 6,841 shares during the quarter. LPL Financial LLC owned approximately 0.06% of TransMedics Group worth $1,315,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Braidwell LP bought a new position in TransMedics Group during the fourth quarter worth $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in TransMedics Group by 16.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company's stock worth $56,307,000 after acquiring an additional 128,474 shares during the period. Mackenzie Financial Corp increased its position in TransMedics Group by 73.0% during the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock worth $51,635,000 after acquiring an additional 349,403 shares during the period. Emerald Advisers LLC increased its position in TransMedics Group by 22.4% during the first quarter. Emerald Advisers LLC now owns 454,794 shares of the company's stock worth $30,599,000 after acquiring an additional 83,083 shares during the period. Finally, Northern Trust Corp increased its position in TransMedics Group by 12.7% during the fourth quarter. Northern Trust Corp now owns 354,622 shares of the company's stock worth $22,111,000 after acquiring an additional 40,093 shares during the period. Institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Performance

TransMedics Group stock traded down $0.66 on Thursday, hitting $116.72. The company's stock had a trading volume of 521,993 shares, compared to its average volume of 1,165,742. The firm has a market cap of $3.98 billion, a P/E ratio of 60.48 and a beta of 2.09. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The company has a fifty day moving average price of $120.41 and a 200-day moving average price of $102.52. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $172.78.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business's revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider owned 13,955 shares of the company's stock, valued at $1,950,909. The trade was a 4.69% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 7.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Oppenheimer boosted their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 17th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Monday. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Morgan Stanley boosted their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Finally, Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a research report on Tuesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, TransMedics Group currently has a consensus rating of "Moderate Buy" and an average target price of $123.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.